AIM AIM ImmunoTech Inc.

Mentions (24)

• Newsglobenewswire.com·1d ago·Neutral

  AIM ImmunoTech Highlights Recent Media Coverage of Ampligen's® Broad-Spectrum Antiviral and Biodefense Potential OCALA, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media coverage of the antiviral potential of Ampligen® (rintatolimod), the Company's investigational dsRNA and highly selective TLR3 agonist immunomodulator.

  View source ↗
• Newsglobenewswire.com·5d ago·Positive

  AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data Recent biotech media features focus on Ampligen's potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC program  Recent biotech media features focus on Ampligen's potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC program

  View source ↗
• Newsproactiveinvestors.com·5d ago·Neutral

  Ionic Rare Earths targets AIM listing as Belfast magnet recycling strategy gathers pace Ionic Rare Earths Ltd (ASX:IXR, OTC:IXRRF) is advancing plans to list its shares on London's AIM market in the fourth quarter of 2026 as it builds its UK presence and progresses commercialisation of its rare earth magnet recycling technology. The proposed AIM admission would complement IonicRE's existing ASX listing and is expected to broaden the company's access to UK and European investors with an interest …

  View source ↗
• Newsglobenewswire.com·6d ago·Positive

  AIM ImmunoTech Discusses Ampligen®'s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video Company highlights supportive survival observations, potential for biomarker-driven patient selection and upcoming Phase 2 DURIPANC milestones

  View source ↗
• Newsproactiveinvestors.com·6d ago·Neutral

  Ondine Biomedical pauses trading to raise fresh investment after positive phase III result Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF), the developer of light-activated nasal disinfection for hospital patients, has suspended trading in its shares while it raises new investment to capitalise on its clinical and commercial progress. The company is one of a growing band of growth companies to use AIM's new Capital Access Window, a voluntary pause in share trading designed to widen the pool of invest…

  View source ↗
• Newsproactiveinvestors.com·8d ago·Neutral

  1947 Oil & Gas starts AIM trading after £50m fundraising and Gulf acquisition 1947 Oil & Gas, a newly listed oil and gas producer focused on US assets, began trading on London's AIM market on Monday with an initial valuation of about £65 million. The company issued 500 million shares at 10p each, raising £50 million through a combination of shares issued to the vendor of Renaissance Offshore and a placing with new investors.

  View source ↗
• Newsproactiveinvestors.com·8d ago·Negative

  1947 Oil & Gas makes AIM debut with ambitions to grow production sharply in coming years 1947 Oil & Gas PLC (AIM:1947) begins trading on AIM today, with shares marked at a premium price and ambitions to lift production from its newly acquired US Gulf of America assets by around 50% over the next two years. In its London IPO, the junior oil and gas raised roughly £30 million at 10p a share to help fund its US$65 million acquisition of Houston-based Renaissance Offshore.

  View source ↗
• Newsproactiveinvestors.com·13d ago·Positive

  Digitalbox eyes creator-led growth as it rides out Meta disruption Digitalbox PLC (AIM:DBOX, FRA:RLXB), the mobile-first digital media group behind The Daily Mash and The Tab, believes the upheaval sweeping digital media presents significant opportunities for nimble players, and says a strong balance sheet leaves it well placed to seize them. The AIM-listed company, which ended June with £2 million of cash, is pressing ahead with a major expansion built around original video and online creators.

  View source ↗
• Newsproactiveinvestors.com·15d ago·Negative

  Coiled Therapeutics fills two cohorts as reworked cancer drug advances Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) has enrolled the first patients into two dose groups testing a reformulated version of its experimental cancer drug. The AIM-listed oncology group said it had signed up three patients each to a twice-daily 120mg cohort and a once-daily 160mg cohort of AO-252, its lead treatment.

  View source ↗
• Newsproactiveinvestors.co.uk·25d ago·Neutral

  Kefi confirms staff safe after fatal Tulu Kapi attack as local investors step up KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF, FRA:KMSA), the AIM-listed explorer developing the Tulu Kapi gold project in Ethiopia, said all employees affected by last week's security incident have been accounted for, with no further casualties. One employee was killed and Kefi suspended development at the site after the attack on 4 September.

  View source ↗
• Newsproactiveinvestors.co.uk·26d ago·Neutral

  Sintana Energy advances deal to acquire KON-16 in Angola Sintana Energy Inc (TSX-V:SEI, OTCQB:SEUSF, FRA:3ZX1, AIM:SEI) has signed definitive agreements for its proposed entry into Angola's Block KON-16, securing an indirect 5% participating interest as the partners work towards a pre-salt exploration well in 2027. The company will pay US$2.5 million for the interest, including US$500,000 already paid to Corcel PLC (AIM:CRCL, FRA:RM4B) and a further US$2 million due on completion.

  View source ↗
• Newsglobenewswire.com·27d ago·Positive

  AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video Company continues to advance Phase 2 DURIPANC study and broader clinical strategy evaluating Ampligen's potential to reshape the tumor microenvironment and enhance checkpoint inhibition

  View source ↗
• Newsproactiveinvestors.co.uk·29d ago·Negative

  Ondine Biomedical strikes deal with Mexico's largest private hospital network Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF), the AIM-listed company behind light-activated antimicrobial therapies, has agreed a partnership with Hospital Ángeles, Mexico's largest private healthcare network, to pilot its Steriwave nasal photodisinfection treatment. The multi-centre pilot follows positive results from Ondine's phase III trial of 5,188 patients across Canadian and US hospitals, which showed a 40% reducti…

  View source ↗
• Newsglobenewswire.com·34d ago·Positive

  AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 Patent protections establish long-duration intellectual property coverage for Ampligen across major European markets and the United Kingdom

  View source ↗
• Newsglobenewswire.com·36d ago·Negative

  AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039 OCALA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office has granted a patent covering the use of the Company's drug Ampligen in combination with the PD-1 checkpoint inhibitor pembrolizumab for th…

  View source ↗
• Newsproactiveinvestors.co.uk·38d ago·Neutral

  Metals One partner rejects claim that Barbrook mine deal has failed Lions Bay Resources has rejected a claim by Vantage Goldfields that its proposed acquisition of the Barbrook gold mine in South Africa has failed, describing the statement as false and misleading. The company is owned by Metals One PLC (AIM:MET1, FRA:HT7, OTCQB:MTOPF), the AIM-listed mining company, and Lions Bay Capital, which trades on the TSX Venture Exchange.

  View source ↗
• Newsglobenewswire.com·40d ago·Neutral

  AIM ImmunoTech Participates in the Virtual Investor ‘Why Now' On-Demand Conference Video webcast now available  here

  View source ↗
• Newsproactiveinvestors.co.uk·40d ago·Neutral

  Alien Metals shares rise 4% after bonanza-grade silver results Shares in Alien Metals Ltd (AIM:UFO, OTC:ASLRF), the AIM-listed minerals exploration and development company, rose 4% to 0.10p on Thursday. The move followed diamond drilling results from the Elizabeth Hill Silver Project in Western Australia, announced by joint venture partner West Coast Silver, which is listed on the Australian Securities Exchange.

  View source ↗
• Newsproactiveinvestors.co.uk·40d ago·Neutral

  Thruvision shares rise over 14% after Canadian government order Shares in Thruvision Group PLC (AIM:THRU, OTC:DIGTF), the walk-through security screening company listed on AIM, rose 14% to 1.40p on Thursday. The move followed news of a new order in Canada, marking Thruvision's first government customer in the country and its first deployment in Canada's entrance security market.

  View source ↗
• Newsproactiveinvestors.co.uk·43d ago·Negative

  Tower Resources tops up working capital as farm-out moves closer to completion Tower Resources PLC (AIM:TRP, FRA:ULF1) has raised £325,000 of additional working capital as it moves closer to completing farm-out transactions in Namibia and Cameroon that are expected to unlock further funding. The AIM-listed group issued around 2.36 billion shares at 0.01375p each, an approximately 8% discount to Friday's closing bid price.

  View source ↗
• Newsproactiveinvestors.co.uk·50d ago·Positive

  Cavendish lifts Optima Health target as annual profit beats forecasts Cavendish raised its price target on Optima Health PLC (AIM:OPT, OTC:OHLTF, FRA:J3N), the occupational health provider, after full-year profit came in ahead of the broker's forecasts and it signalled growing confidence in the company's medium-term targets. The AIM-listed group reported adjusted earnings before interest, tax, depreciation and amortisation of £20.1 million for the year to March, around 12% above Cavendish's esti…

  View source ↗
• Newsglobenewswire.com·55d ago·Positive

  AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense' Article Article by CEO Thomas K. Equels calls for proactive evaluation of broad-spectrum antiviral countermeasures before novel viral threats emerge

  View source ↗
• Newsproactiveinvestors.co.uk·55d ago·Positive

  Bravura Solutions shares climb as AIM newbie marks 76% jump in cash earnings Bravura Solutions Ltd (AIM:BVS), the wealth management software firm that floated last month, got off to a positive start on Wednesday after reporting a 76% jump in underlying cash EBITDA to A$77.1 million for FY26 and unveiled an on-market share buyback of up to A$50 million, alongside A$67.3 million of final and special dividends. Underlying revenue increased 9.6% to A$282.6 million despite second-half currency headwi

  View source ↗
• Newsproactiveinvestors.co.uk·57d ago·Neutral

  Thruvision shares surge 46% to 0.91p on £3m Asian airport contract Thruvision Group PLC (AIM:THRU, OTC:DIGTF) shares jumped 46% to 0.91p after the security screening group landed its largest contract in Asia to date. The AIM-listed company said its principal regional partner has won a deal to deploy Thruvision systems across several major airports in South-East Asia, generating more than £3 million of revenue.

  View source ↗